12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vibativ telavancin regulatory update

FDA's Anti-Infective Drugs Advisory Committee will meet on Nov. 29 to discuss an NDA from Theravance for Vibativ telavancin to treat nosocomial pneumonia, including ventilator-associated pneumonia known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA) or Streptococcus pneumoniae. The injectable lipoglycopeptide antibiotic is approved in the U.S. and Canada to treat complicated skin and skin structure infections (cSSSIs) caused by susceptible Gram-positive bacteria, and in the EU to treat nosocomial pneumonia, including...

Read the full 349 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >